Brief by Shorts91 Newsdesk / 03:41pm on 19 Dec 2024,Thursday Health & Wellness
AIIMS researchers in New Delhi have developed chimeric antigen receptor (CAR) T-cell therapy targeting multiple myeloma, a severe blood cancer. This breakthrough involves genetically modifying a patient’s T cells to identify and destroy cancer cells effectively. Initial animal trials have shown promising results. Prof Mayank Singh of BRAIRCH, AIIMS, noted that this therapy could offer an affordable alternative to expensive FDA-approved treatments unavailable to many Indian patients. Clinical validation is pending, but researchers aim to make the treatment accessible. With India facing rising cancer cases, this innovation could significantly reduce the disease burden.
